Recce's R327 found effective against E.coli during clinical trial
Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online